Disappointing Merck drug news underscores critical next steps in Alzheimer’s fight
Credit: UsAgainstAlzheimer's WASHINGTON, DC, Feb. 17, 2017 -- The recent announcement that Merck is halting a Phase II/III study for a promising Alzheimer's treatment (verubecestat)...